Currently out of the existing stock ratings of Laura Chico, 329 are a BUY (72.63%), 114 are a HOLD (25.17%), 10 are a SELL (2.21%).

Laura Chico

Work Performance Price Targets & Ratings Chart

Analyst Laura Chico, currently employed at WEDBUSH, carries an average stock price target met ratio of 58.81% that have a potential upside of 40.03% achieved within 240 days.

Laura Chico’s has documented 878 price targets and ratings displayed on 51 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on ARDX, Ardelyx at 18-Aug-2026.

Wall Street Analyst Laura Chico

Analyst best performing recommendations are on MLND (MILLENDO THERAPEUTICS).
The best stock recommendation documented was for APLS (APELLIS PHARMACEUTICALS) at 8/7/2023. The price target of $29 was fulfilled within 4 days with a profit of $5.35 (22.62%) receiving and performance score of 56.55.

Average potential price target upside

of $41.26 (35.62%) on KRTX (KARUNA THERAPEUTICS).
of $35.65 (32.16%) on ALXN (ALEXION PHARMACEUTICALS).
of $24.52 (217.86%) on SA (SEABRIDGE GOLD).

ACER Acer Therapeutics ALXN Alexion Pharmaceuticals APLS Apellis Pharmaceuticals APTX Aptinyx ARDX Ardelyx BHVN Biohaven Pharmaceutical Holding Co Ltd BIIB Biogen DNLI Denali Therapeutics KRTX Karuna Therapeutics NBIX Neurocrine Biosciences PRAX Praxis Precision Medicines RARE Ultragenyx RTRX Travere Therapeutics SAGE Sage Therapeutic TSHA Taysha Gene Therapies TVTX Travere Therapeutics VIE Viela Bio XENE Xenon Pharmaceuticals PRVL Prevail Therapeutics VYGR Voyager Therapeutics DSGN Design Therapeutics IMPL Impel Neuropharma VERA Vera Therapeutics STOK Stoke Therapeutics DOVA Dova Pharmaceuticals MLND Millendo Therapeutics PEPG PepGen Ltd VIGL Vigil Neuroscience VRTX Vertex Pharmaceuticals ATXS Astria Therapeutics PASG Passage Bio BMRN Biomarin Pharmaceutical EWTX Edgewise Therapeutics KDNY Chinook Therapeutics LBPH Longboard Pharmaceuticals PHVS Pharvaris BV RLYB Rallybio Corp VRDN Viridian Therapeutics AVTE Aerovate Therapeutics GOSS Gossamer Bio ANRO Alto Neuroscience DNTH Dianthus Therapeutics LRMR Larimar Therapeutics OVID Ovid Therapeutics SLDB Solid Biosciences LLC BCRX BioCryst Pharmaceuticals DOV Dover KD Kyndryl Holdings LB L Brands SA Seabridge Gold TRML Tourmaline Bio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jonathan Aschoff (ROTH MKM)